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 Abstract
The aim of this article is to present the safety and efficacy of intradetrusor botulinum toxin injections in the treatment 
of non-neurogenic overactive bladder in pediatric patients. 
The electronic database MEDLINE (1966-2009) was searched including the following entries: non-neurogenic 
overactive bladder and botulinum overactive bladder. Data on the investigation topic are scarce. 
Most of the papers concern neurogenic overactive bladder in adults, with only a few dealing with children with 
neurological disturbances. Therefore, the following paper presents a case of botulin toxin treatment in girl with 
overactive bladder. The patient did not tolerate the standard  anticholinergic therapy and did not present neurollogical 
disturbances. Successful outcome allows us to state that intradetrusor botulinum toxin type A injection is a promising 
new treatment method in the refractory cases of non-neurogenic pediatric overactive bladder. 
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Introduction
Overactive	 bladder	 (OAB)	 is	 characterized	 by	 involuntary	
and	unpredictable	 detrusor	muscle	 contractions,	 causing	 an	 in-
creased	micturition	frequency	accompanied	by	a	strong	desire	to	
void,	 leading	 to	 incontinence	episodes	 in	30%	of	patients.	The	
exact	 percentage	of	 children	 suffering	 from	 these	 symptoms	 is	
currently	not	known	but	epidemiological	studies	in	Europe	and	
the	United	States	show	that	this	condition	affects	around	16.5%	
of	 adult	 population	 [1,	 2].	 Currently	 anticholinergics	 are	 the	
mainstay	of	OAB	therapy	but	the	tolerability	of	these	agents	is	
limited	 due	 to	 side-effects,	 such	 as	 dry	 mouth,	 dizziness,	 and	
somnolence	[3].	Since	bothering	side-effects	definitely	could	af-
fect	compliance,	and,	in	the	end	efficacy	of	the	treatment,	there	is	
a	need	for	treatment	modalities	that	both	effectively	control	OAB	
symptoms	and	can	be	 tolerated	 in	 the	 long	 term.	There	 is	 also	
substantial	group	of	patients	who	do	not	respond	to	anticholin-
ergic	therapy.	Therefore,	the	solution	for	the	nonresponders	and	
patients	with	especially	bothersome	side	effects	may	be	intrade-
trusor	botulinum	toxin	therapy.	
For	the	first	time	effects	of	botulinum	toxin	ingestion	were	
described	in	the	late	1700s	in	Germany	in	cases	of	sausage	poi-
soning.	However,	it	was	not	until	1897	when	this	most	potent	bio-
logic	toxin	was	isolated	from	the	anaerobic	bacteria	(Clostridium	
botulinum)	by	van	Ermengem	[4].	Of	the	seven	distinctly	isolated	
and	structurally	similar	serotypes	of	botulinum	toxin,	only	types	
A	 and	B	 have	 been	 used	 in	medicine.	The	 product	 containing	
serotype	A	of	botulinum	toxin	(BTX-A)	is	used	in	children	and	
currently	 is	 becoming	 a	 standard	 in	 the	 treatment	 of	 spasticity	
secondary	to	cerebral	palsy	[5].
The	 activity	 of	 botulinum	 toxin	within	 the	 neuromuscular	
junction	has	been	described	and	consists	of	inhibition	of	acetyl-
choline	release	at	the	presynaptic	level,	resulting	in	striated	mus-
cle	 relaxation	 [6].	 It	does	 so	by	cleavage	of	 the	 synaptosomal-
associated	protein	with	a	molecular	weight	of	25	kD	(SNAP-25),	
which	physiologically	is	responsible	for	the	docking	of	vesicles	
containing	acetylocholine	[7].	The	lack	of	acetylocholine	in	syn-
apse	 cleft	 results	 in	 suppressing	 of	muscle	 contractility.	 In	 the	
urinary	bladder	botulinum	 toxin	also	appears	 to	have	an	effect	
on	specific	sensory	pathways,	which	may	explain	its	efficacy	in	
reducing	urgency	[8,	9].	
Botulinum	toxin	has	been	found	 to	 inhibit	 the	 release	of	a	
number	 of	 other	 neurotransmitters	 such	 as,	 adenosine	 triphos-
phate,	and	neuropeptides:	substance	P,	glutamate,	protein	kinase	
C	and	to	down-regulate	the	expression	of	purinergic	and	capsai-
cin	receptors	on	afferent	neurons	within	the	bladder	wall	[8,	10].	
All	these	data	support	the	view	that	botulinum	toxin	works	in	the	
detrusor	overactivity	and	overactive	bladder	both,	by	sensory	and	
motor	pathways.
After	introduction	of	botulinum	toxin	into	treatment	of	de-
trusor	overactivity	 in	adults	 there	 is	growing	evidence	 that	 this	
regimen	could	be	also	efficacious	in	children.	Further	support	for	
this	 strategy	 came	 from	 the	 case	of	14-year	old	neurologically	
intact	girl,	noncompliant	to	the	standard	anticholinergic	therapy.
Case report 
Since	 early	 childhood	 our	 patient	 has	 been	 experiencing	
enuresis	nocturna	and	symptoms	of	OAB	with	urinary	 inconti-
nence.	The	diary	showed	15	micturitions	daily	with	volume	from	
12	to	25mls	and	first	morning	micturition	with	average	volume	of	
110ml.	The	patient’s	siblings	also	presented	urinary	tract	symp-
toms,	the	younger	sister	receives	oxybutynin	for	OAB	while	the	
brother	is	treated	with	desmopressin	for	enuresis	nocturna.	Blad-
der	sonography	did	not	show	residual	urine,	uroflowmetry	results	
were	within	normal	range.	The	patient	was	treated	with	oral	oxy-
butynin	chloride		(5mg	TID)	and	single	evening	dose	of	desmo-
pressin	(0.1mg).	The	response	was	excellent,	patient	noted	total	
abatement	of	OAB	symptoms	and	enuresis	nocturna.	However,	
after	 2	months	 the	 girl	 became	 noncompliant,	 she	 stopped	 the	
therapy	and	all	 symptoms	relapsed.	Since	 the	patient	withdrew	
consent	 to	 oxybutynin	 chloride/desmopressin	 regimen,	 botuli-
num	 toxin	 was	 proposed	 instead.	After	 obtaining	 an	 informed	
consent	from	the	patient	and	her	parents,	100	U	of	BTX-A	(Bo-
tox)	was	given	in	20	intradetrusor	injections	sparing	trigone.	The	
rigid	 cystoscope	was	used	 (diameter	 9mm)	 and	procedure	was	
performed	 under	 short-time	 general	 anesthesia	 which,	 in	 our	
opinion,	 is	obligatory	 in	pediatric	patients	due	 to	high	 level	of	
anxiety.	 Initial	 response	was	 good,	we	noted	marked	 improve-
ment	of	OAB	symptoms	during	day.	However,	during	the	follow-
up	visit,	2	weeks	later,	the	patient	complained	that	all	symptoms	
returned	to	the	pretreatment	severity.	
 Streszczenie
Celem pracy była analiza bezpieczeństwa i skuteczności podawanej dopęcherzowo toksyny botulinowej u dzieci 
z zespołem pęcherza nadreaktywnego o podłożu nieneurogennym. 
Korzystając z bazy danych MEDLINE dokonano analizy piśmiennictwa opublikowanego w latach 1966-2009. 
Wyszukiwanie artykułów przeprowadzono w oparciu o następujące terminy: non-neurogenic overactive bladder, 
botulinum overactive bladder. 
Ogromna większość publikacji dotyczy zastosowania toksyny botulinowej u dorosłych lub dzieci z neurogenną 
postacią zespołu pęcherza nadreaktywnego. Zaskakująca jest niewielka liczba artykułów dotyczących zastosowania 
toksyny botulinowej u dzieci z nieneurogenną postacią zespołu pęcherza nadreaktywnego. Z tego względu praca 
została uzupełniona prezentacją przypadku skutecznej terapii toksyną botulinową u dziewczynki bez zaburzeń 
neurologicznych, zgłaszającej objawy pęcherza nadreaktywnego, jednak nie tolerującej terapii lekami o działaniu 
antycholinergicznym.
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The	 combination	 of	 oxybutynin	 chloride	 and	 desmopres-
sin	was	started	with	good	response	but	patient	again	stopped	the	
treatment	after	a	short	time.	We	proposed	another	Botox	therapy	
and	200	U	was	given	in	the	same	manner.	Three	months	follow-
ing	the	injection	the	girl	remains	dry	and	free	of	OAB	symptoms	
but	desmopressin	treatment	had	to	be	started	to	control	enuresis	
nocturna.
Discussion
Botulinum	toxin	type	A	has	been	used	to	treat	a	spectrum	of	
neuromuscular	and	neuro-urological	diseases.	In	urology	BTX-A	
was	first	investigated	in	1990	in	the	treatment	of	detrusor	external	
sphincter	dyssynergia	in	adult	patients	with	spinal	cord	injury	and	
currently	also	 in	 idiopathic	overactive	bladder	[11,	12,	13,	14].	
Twelve	years	later	Schulte-Baukloh	et	al.	[15]	reported	the	first	
study	showing	the	effects	of	botulinum-A	toxin	in	children	with	
neurogenic	detrusor	overactivity.
Currently,	in	pediatric	urological	applications	the	two	cate-
gories	of	botulinum	toxin	treatment	are	under	clinical	evaluation:	
the	detrusor	overactivity	refractory	to	anticholinergics	and	void-
ing	dysfunction.	The	use	of	BTX-A	in	the	treatment	of	children	
with	 detrusor	 overactivity	 is	 definitely	 a	 second-line	 treatment	
option	only	when	intolerance	or	failure	after	antimuscarinics	oc-
cur.	The	main	clinical	goal	is	to	improve	urinary	symptoms	and	
quality	of	life.	There	is	currently	no	consensus	about	the	optimal	
treatment	in	children.	Dosage,	number	and	location	of	injections,	
type	of	cystoscope,	and	type	of	anesthesia	should	be	verified	in	
well,	designed	clinical	trials.	
The	safety	of	intradetrusor	injections	in	children	is	another	
issue.	 In	animal	studies	 the	 lethal	dose	of	botulinum	toxin	was	
39-40U/kg	 [16].	By	extrapolation	one	can	calculate	 that	 for	an	
adult	person	weighing	70	kg	 the	 lethal	dose	will	be	as	high	as	
2800U.	 In	urogynecology	usually	a	single	dose	doesn’t	exceed	
300	U	(50-300	U)	and	 therefore	 it	 is	very	unusual	 that,	 such	a	
dose,	when	properly	applied,	could	really	exert	systemic	effects.	
The	most	common	symptoms	after	intradetrusor	botulinum	toxin	
injection	are:	detrusor	areflexia	with	transient	necessity	of	cath-
eterization,	increased	post-void	urine	residual	volume	and	spas-
ticity	of	lower	limbs	[17,	18].	
In	our	case	we	used	100	U	of	Botox,	followed	by	injections	
of	200	U	of	the	same	medication.	Our	patient	did	not	report	any	
side	effects	related	to	this	regimen.	Good	clinical	response	after	
second	course	of	the	treatment	is	particularly	worth	noting.	We	
believe	that	that	these	positive	effects	could	be	related	to	combi-
nation	of	the	two	doses	of	BTX-A.	Of	course,	it	is	far	too	early	
to	establish	of	the	treatment	regimen	in	pediatric	OAB	refractory	
to	the	anticholinergic	therapy.	No	real	systemic	side	effects	have	
been	reported	when	the	appropriate	dose	has	been	used	[5].	Main	
contraindications	 to	 injection	 of	 botulinum	 toxin	 are:	 motoric	
neuropathy	 such	 as	myasthenia	 gravis	 or	Lamberta-Eaton	 syn-
drome	and	also	concomitant	treatment	with	aminoglycosides.
Recently,	Game	et	al.	[19]	presented	a	meta-analysis	of	six	
previously	published	studies	concerning	BTX-A	use	in	children	
with	neurogenic	detrusor	overactivity.	 In	analyzed	material	 the	
amount	of	injected	BTX-A	ranged	from	5	to	12U/kg	with	a	maxi-
mal	dose	of	360	U.	The	mean	number	of	injection	sites	were	30	
(range:	 10-50),	BTX-A	was	 given	 in	 the	 bladder	wall,	 sparing	
the	 trigone,	 under	 rigid	 cystoscopic	 guidance	 and	 under	 gen-
eral	anesthesia.	Efficacy	of	treatment	was	measured	in	terms	of	 
continence	 restoration	 and	 urodynamic	 findings.	The	mean	 re-
duction	of	urinary	 incontinence	 score	varied	 from	baseline	be-
tween	40%	and	80%	but	it	should	be	pointed	out	that	65%-87%	
of	children	became	completely	continent.	Statistically	significant	
positive	influence	of	BTX-A	treatment	on	urodynamic	variables	
were	demonstrated	in	all	analyzed	studies.	Botulinum	toxin	injec-
tion	caused	maximum	detrusor	pressure	(Pdetmax)	reduction	in	
range	from	33	to	55%.		
Moreover,	in	most	of	the	studies	mean	Pdetmax	was	reduced	
with	BTX-A	 to	 <40cm	H2O,	which	 is	 regarded	 as	 the	 desired	
value	for	upper	urinary	 tract	protection.	The	reduction	 in	Pdet-
max	was	accompanied	by	an	increase	in	maximum	cystometric	
capacity	(MCC)	varying,	when	comparing	to	baseline,	between	
110	to	200ml.	From	clinical	point	of	view	that	was	of	critical	im-
portance	because	patients	with	a	low	mean	MCC	at	baseline	ex-
perienced	a	mean	increase	in	MCC	as	high	as	100-170%.	In	most	
studies	authors	noticed	the	improvement	of	urine	continence	and	
urodynamic	parameters	within	2	weeks	after	BTX-A	injections	
and	these	positive	effects	persisted	from	2	weeks	up	to	6	months	
[20].	
Until	now	only	one	report	was	published	concerning	BTX-A	
treatment	in	children	with	non-neuropathic	detrusor	overactivity	
[21].	Study	group	consisted	of	21	children	(11	boys,	10	girls;	aged	
8-14	 years)	who	were	 given	 100IU	 of	Botox,	with	 12	months	
follow-up	in	15	patients.	After	first	injection,	9	patients	showed	
a	full	 response	as	defined	by	the	authors	as	no	urgency	and	no	
urine	 leakage	during	 the	day.	Additionally	3	patients	 showed	a	
partial	response	(50%	reduction	in	urgency	and	incontinent	epi-
sodes)	of	which	one	responded	well	after	repeat	injection.	Three	
children	showed	no	response	at	all.	The	MCC	was	shown	to	have	
increased	 from	167	 to	 271ml.	 	Eight	 children	 out	 of	 15	main-
tained	a	response	at	1	year,	which	is	longer	that	usually	observed	
among	adult	patients.	
Conclusions
The	evidence	supports	 the	use	of	BTX-A	as	a	safe	and	ef-
ficacious	 treatment	 in	 children	 with	 detrusor	 overactivity	 and	
voiding	dysfunction	refractory	to	anticholinergics.	Studies	have	
demonstrated	that	BTX-A	has	long-lasting	and	beneficial	effect	
on	urinary	symptoms,	urodynamic	parameters	and	children	qual-
ity	of	life.	
However,	it	should	be	pointed	out	that	data	on	pediatric	use	
of	 botulinum	 toxin	 is	 limited	 by	 the	 lack	 of	 controlled	 studies	
and	the	fact	that	most	of	the	studies	involved	small	numbers	of	
individuals.
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